Interim Results for six months ended 30 September 2007
20 November 2007
London, UK, Brentwood, TN, 20 November 2007 - Protherics PLC (“Protherics” or the “Company”), the biopharmaceutical company focused on critical care and cancer, today announces its unaudited interim results for the six months ended 30 September 2007.
More information
Patient recruitment in phase 2b “DEEP” study in severe pre-eclampsia completed ahead of schedule
20 November 2007
London, UK; Brentwood, TN, US; 20 November 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that the last patient in the phase 2b Digibind® Efficacy Evaluation in Pre-eclampsia (DEEP) study in severe pre-eclampsia, a potentially life-threatening condition of pregnancy, has been enrolled and treated.
More information
Protherics licenses its CoVaccine HT™ adjuvant to Nobilon for influenza vaccine indications
26 September 2007
London, UK and Boxmeer, The Netherlands; 26 September 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, and Nobilon International B.V. (“Nobilon”), part of Organon, the human health care business unit of Akzo Nobel, today announced that Nobilon has licensed Protherics’ CoVaccine HT™ adjuvant for use in pandemic influenza vaccines and seasonal influenza vaccines in elderly people.
More information
Protherics signs ReGel™ licensing agreement with Myungmoon Pharm.
25 September 2007
London, UK; Brentwood, TN, US; 25 September 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that it has signed a licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company, granting it the rights to develop anti-inflammatory products using Protherics’ local, sustained release drug delivery system ReGel™.
More information
Board Changes - Update
10 August 2007
London, UK; Brentwood, TN, US: 10 August 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that Rolf Soderstrom has now commenced as Finance Director of Protherics, following the announcement of his appointment on 26 April 2007.
More information
AGM and Interim Management Statement
26 July 2007
London, UK; Brentwood, TN, US; 26 July 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, provides its Interim Management Statement ahead of the Company’s AGM at midday today.
More information
Prolarix™ dose selected for phase 2 liver cancer study
12 July 2007
London, UK; Brentwood, TN, US; 12 July 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the maximum tolerated dose (“MTD”) of Prolarix™ has been determined in a phase 1 study being conducted under the auspices of Cancer Research UK. Prolarix™ is a novel targeted prodrug therapy being developed for the treatment of primary liver cancer (hepatocellular carcinoma) and other selected tumours.
More information
Preliminary results for year ended 31 March 2007
5 June 2007
London, UK, Brentwood, TN, 5 June 2007 - Protherics PLC, (“Protherics” or the “Company”), the biopharmaceutical company focused on critical care and cancer, today announces its preliminary results for the 12 months ended 31 March 2007.
More information
Notification of Preliminary Results
25 May 2007
London, 25 May 2007: Protherics PLC (“Protherics”), the biopharmaceutical company focused on critical care and cancer, will be announcing its preliminary results for the year ended 31 March 2007, on Tuesday 5 June 2007.
More information
Protherics presents encouraging OncoGel™ phase 2a oesophageal cancer data at leading US conference
22 May 2007
London, UK; Brentwood, TN, US; 22 May 2007 - Protherics PLC (“Protherics” or the“Company”), the international biopharmaceutical company focused on critical care and cancer,announces that positive phase 2a data supporting the development of OncoGel™ in oesophageal cancer were presented yesterday during a poster session at the DigestiveDisease Week (“DDW”) 2007 Conference in Washington, DC. The poster was selected as a “Poster of Distinction,” placing it in the top 10% of all American Gastroenterology Association(AGA) Institute abstracts selected for poster presentation.
Please click here for the a PDF of the OncoGel Poster.
More information
Voraxaze™ Update
22 May 2007
London, UK; Brentwood, TN, US; 22 May 2007 - Protherics PLC (“Protherics” or the“Company”), the international biopharmaceutical company focused on critical care and cancer, today provided an update on its Voraxaze™ marketing applications in the US and EU. Voraxaze™ is an adjunctive therapy for patients with impaired renal function who are experiencing, or at risk of, toxicity from methotrexate (“MTX”), a widely used anti-cancer agent.
More information
Board changes and trading update
26 April 2007
London, UK; Brentwood, TN, US; 26 April 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces a number of changes to its Board and provides a trading update to the market.
More information
Protherics initiates OncoGel™ phase 1/2 brain cancer study
27 March 2007
London, UK; Brentwood, TN, US; 27 March 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the enrolment of the first patient in a clinical study to investigate the use of OncoGel™, a novel formulation of paclitaxel for local administration, as an adjuvant treatment to surgical removal of the tumour in patients with recurrent glioblastoma multiforme (GBM).
More information
Protherics to receive £10 million milestone from AstraZeneca
12 March 2007
London, UK; Brentwood, TN, US; 12 March 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that a £10 million milestone payment from AstraZeneca has been triggered as a result of the successful scale-up of the CytoFab™ manufacturing process to a 600 litre batch size. This milestone will be included in the Company’s results for the financial year ending 31 March 2007 and is expected to be received in April.
More information
Appointment of Non-executive Director
24 January 2007
London, UK; Brentwood, TN, US; 24 January 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, is pleased to announce the appointment of Dr Jacques Gonella as a Non-executive Director, with effect from today. He will serve on the Company’s audit, nomination and remuneration committees.
More information
Protherics awarded £1m SMARTCymru grant
16 January 2007
Protherics has been granted £1 million through the Welsh Assembly Government’s SMARTCymru programme. The programme is designed to assist Welsh individuals and small and medium-sized businesses to undertake research and development into new technology, products and processes. The grant will be used to support the manufacture of Protherics’ promising anti-sepsis drug CytoFab™, which is being developed in partnership with AstraZeneca.
Voraxaze™ Update
11 January 2007
London, UK; Brentwood, TN, US; 11 January 2007 - Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today provides an update on progress with Voraxaze™ in the United States and Europe. Voraxaze™ is an adjunctive therapy for patients experiencing, or at risk of, toxicity from methotrexate (“MTX”), a widely used anti-cancer agent.
More information
Protherics submits DigiFab™ New Drug Submission in Canada
8 January 2007
London, UK; Brentwood, TN, US: 8 January 2007 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that it has submitted a New Drug Submission to the Health Products and Food Branch of Health Canada for DigiFab™. DigiFab™ is the leading digoxin antidote in the US where it is approved for the treatment of life-threatening or potentially life-threatening digoxin toxicity or overdose.
More information
Completion of MacroMed Acquisition
4 January 2007
London, UK; Brentwood, TN, US; 4 January 2007 - Protherics PLC (“Protherics” or the ”Company”), the international biopharmaceutical company focused on critical care and cancer, announces that its acquisition of MacroMed, Inc., a private US based drug development and manufacturing company, has completed at 4.00 pm GMT (9.00 am MST) today.
More information
Result of Placing and Open Offer
3 January 2007
London, UK; Brentwood, TN, US; 3 January 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announced on 7 December 2006 the signing of three agreements to expand its development pipeline and the issue of 58,715,544 new Ordinary Shares through a placing for cash and a proposed Placing and Open Offer at an issue price of 65 pence per share, underwritten by NomuraCode Securities Limited and Piper Jaffray Ltd.
More information
|